Marshall Edwards Inc., Annual General Meeting, Dec 08, 2009, at 13:00 US Eastern Time. Location: Morgan,Lewis & Bockius LLP, 101 Park Avenue, New York, NY 10178,United States. Agenda: To elect one member to the board of directors; to ratify the appointment of the independent auditor for the fiscal year ending June 30, 2010; and to consider and act on such matters as may properly come before the Annual Meeting and any adjournment thereof.

Marshall Edwards Inc. released data demonstrating that the efficacy of NV-128 in animal xenograft models is achieved without apparent toxicity. NV-128 is a novel flavonoid small molecule mTOR inhibitor, capable of inhibiting both mTORC1 and mTORC2 pathways which are central to the aberrant proliferative capacity of both mature cancer cells and cancer stem cells. The data demonstrated that NV-128 has much greater safety than some other mTOR inhibitors in mice bearing human ovarian cancer xenografts. Most of the current compounds acting on this pathway are analogs of rapamycin, known as rapalogs. Rapamycin and its analogs are regarded as the archetypal inhibitors of mammalian target of rapamycin or mTOR. In addition to their reported toxicities, rapalogs have been shown to contribute to the development of drug resistant tumors and ultimately reduced effectiveness over time due to their inability to efficiently inhibit mTORC2, a complex of mTOR with 'rictor' (rapamycin-insensitive companion of mTOR).

On September 16, 2009, Marshall Edwards, Inc. received notice from The NASDAQ Stock Market (NASDAQ) stating that for the last 30 consecutive business days, the bid price for the Company�s common stock had closed below the minimum $1.00 per share required for continued inclusion on the NASDAQ Global Market under NASDAQ Rule 5450(a)(1). The notification letter states that the Company will be afforded a grace period of 180 calendar days, or until March 15, 2010, to regain compliance with the minimum bid price requirement in accordance with NASDAQ Rule 5810(c)(3)(A). In order to regain compliance, shares of the Company�s common stock must maintain a minimum bid closing price of at least $1.00 per share for a minimum of ten consecutive business days during the grace period. The Company intends to actively monitor the bid price of its common stock between now and March 15, 2010. On September 22, 2009, the Company issued a press release announcing its receipt of the notice from NASDAQ.